What are the opening hours?

Monday 9am - 6pm Tuesday 9am - 6pm Wednesday 9am - 6pm Thursday 9am - 6pm Friday 9am - 6pm Saturday 9am - 12pm

Lucence

Lucence is a precision health company committed to earlier detection for better health.

Lucence makes ultrasensitive non-invasive liquid biopsy tests to provide doctors and their patients life-changing information to enable earlier detection and effective treatment. Headquartered in Palo Alto and Singapore, Lucence supplies personalized cancer care services through twin CLIA-licensed laboratories in the United States and Singapore.

07/28/2026

How can clinicians obtain actionable genomic insights for patients with advanced lung cancer and CNS involvement?

Because the blood-brain barrier can limit the detection of intracranial tumor DNA in plasma, cerebrospinal fluid (CSF) liquid biopsy may provide clinically valuable molecular information in selected patients.

Join Dr. Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, and Dr. Tan Min-Han, Founder and CEO of Lucence, for a clinical discussion on the role of LiquidHALLMARK® CSF for molecular profiling in patients with CNS disease.

The discussion will cover:
• When CSF molecular profiling may be considered
• Clinical evidence supporting CSF liquid biopsy
• Practical applications in the management of CNS metastases in advanced lung cancer

📅 Wednesday, July 29, 2026
🕗 8:00 PM ET (US & Canada)

Register by scanning the QR code on the event flyer, or by clicking this link: https://lnkd.in/efWyQVN8

We look forward to seeing you there.

07/22/2026

A clear scan is often the first sign of good news after treatment. This year's ASCO meeting asked a deeper question: what is happening at the molecular level, and how early can we know?

Across several major trials, molecular testing moved earlier: into resected disease, into treatment-switch decisions, and closer to the moment care actually changes.

One example: in stage II colon cancer, ctDNA-positive patients guided to adjuvant chemotherapy had a 3-year recurrence rate of 19%, compared with 62% for observation alone.[1]

Read the full recap of what ASCO 2026 signaled for molecular testing: https://www.lucence.com/clinical-insights/the-right-signal-at-the-right-time-liquid-biopsy-trends-from-asco-2026

[1] Folprecht G, et al. J Clin Oncol. 2026;44(17_suppl):LBA3500.

07/10/2026

When an MCED test says it screens for hundreds of cancer subtypes, what does that actually mean?

Subtypes, anatomical sites, and cancer types are not the same thing. Counting them separately is not the same as validating separate screening categories.

Performance also varies widely by stage. In one clinical validation study, sensitivity at stage I was 16.8%. At stage IV: 90.1%.[1]

And a positive result is not a diagnosis. Follow-up imaging, specialist review, and in some cases biopsy are still needed.

Three questions worth asking before and after any MCED test:
1. What proportion of cancer incidence and mortality does this test cover?
2. How does sensitivity vary by cancer type and stage?
3. What follow-up pathway follows a positive result?

Read more: https://www.lucence.com/clinical-insights/mced-tests-promise-limitations-and-3-questions-worth-asking

[1] Klein EA, et al. Ann Oncol. 2021; 32(9): 1167–1177.

07/01/2026

Cancer prevention may begin long before cancer itself.

Many common risk factors, from smoking and alcohol to inactivity and air pollution, ultimately affect the same biological pathways linked to aging: inflammation, oxidative stress, metabolic dysfunction, and DNA damage.

In our latest article, we explore why longevity medicine and cancer prevention are more connected than many people realize.

Read more: https://www.lucence.com/clinical-insights/why-cancer-prevention-begins-with-longevity-medicine

06/25/2026

We are honored to welcome Dr. Guru Sonpavde, Director of Phase I Clinical Research and Genitourinary Oncology and Endowed Chair of Bladder Cancer Research at Advent Health Cancer Institute, and Professor of Medicine at the University of Central Florida, Orlando, Florida to the Lucence Medical Advisory Board.

A recognized leader in genitourinary oncology, Dr. Sonpavde brings extensive expertise in translational research, therapeutic innovation, and patient-focused cancer care. His guidance will help shape Lucence’s continued efforts to advance precision diagnostics and deliver clinically meaningful insights to physicians and patients around the world.

We look forward to working together to drive the future of precision oncology.

Visit our website: www.lucence.com

06/24/2026

When Angelina Jolie learned she carried a BRCA1 mutation, the result did not tell her she had cancer.

It told her she was at increased risk of developing cancer in the future.

That distinction highlights an important difference between two increasingly common applications of next-generation sequencing (NGS):
• Cancer risk testing asks: "Am I at increased risk?"
• Cancer screening asks: "Is cancer present now?"

While they answer different questions, both aim to create opportunities for earlier action.

In our latest article, we explore how risk testing and cancer screening complement one another.

Read the full article: https://www.lucence.com/clinical-insights/cancer-risk-testing-vs-cancer-screening-whats-the-difference

06/17/2026

Some health risks begin long before routine tests show anything unusual.

Clonal hematopoiesis (CH) starts when blood stem cells acquire mutations that allow certain clones to expand over time. These changes become more common with age and may contribute to inflammation, cardiovascular disease, and blood cancer risk.

Evidence increasingly links CH to heart attack, stroke, and hematologic malignancy risk, even in people without traditional cardiovascular risk factors.

As sequencing becomes more accessible, CH is moving from a research concept toward a clinical discussion about hidden risk, prevention, and earlier intervention.

Read the full article here: https://www.lucence.com/clinical-insights/clonal-hematopoiesis-the-somatic-risk-factor-hiding-in-plain-sight

06/11/2026

Clinical progression requires a fresh look at a tumor's genetics.

Dr. Shane Dormady shares how he used liquid biopsy for a metastatic breast cancer patient showing signs of multiple new metastases. The test successfully identified a critical PIK3CA mutation, allowing him to change the treatment strategy to a targeted therapy that delivered a complete response.

Watch the full video here: https://www.lucence.com/patient-stories/dr.-shane-dormady

https://www.facebook.com/reel/26212214308457120/

06/10/2026

After curative-intent treatment, recurrence can begin below what imaging, examination, or protein markers can detect. Minimal residual disease, or MRD, asks a different question: is a tumor-derived molecular signal still present?

In colorectal surveillance, serial plasma sequencing flagged recurrence about 8.7 months before radiologic imaging. [1] In 2026, the first FDA approval associated with MRD in solid tumors arrived in muscle-invasive bladder cancer. [2]

One result is a moment. Serial testing is a pattern.

New this week: what MRD can, and cannot, reveal after treatment.

Read the full article here: https://www.lucence.com/clinical-insights/when-the-scan-is-clear-how-mrd-is-changing-cancer-surveillance-after-treatment

[1] Reinert T, et al. JAMA Oncol. 2019; 5(8): 1124–1131.
[2] U.S. Food and Drug Administration. May 2026.

06/09/2026

We are honored to welcome Dr. Shane Dormady, Medical Director of El Camino Health Cancer Center, to the Lucence Medical Advisory Board.

Dr. Dormady brings deep experience in clinical oncology along with a strong commitment to delivering thoughtful, patient-centered care. His perspective will help support Lucence as we continue advancing precision diagnostics and expanding access to actionable insights for physicians and patients worldwide.

We are excited for the collaboration ahead and the impact we can create together!

Address

3520 W Bayshore Road
Palo Alto, CA
94303

Opening Hours

Monday	9am - 6pm
Tuesday	9am - 6pm
Wednesday	9am - 6pm
Thursday	9am - 6pm
Friday	9am - 6pm
Saturday	9am - 12pm

Telephone

+18885823623

Website

http://www.lucence.com/

Alerts

Be the first to know and let us send you an email when Lucence posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Lucence:

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Practice
Claim ownership or report listing

Want your practice to be the top-listed Clinic in Palo Alto?